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Abstract
Background: Both omeprazole and its S enantiomer (esomeprazole) have been available and used to treat
symptoms of gastroesophageal reflux disease (GERD) and conditions associated with excessive stomach acid
secretion for more than a decade. Controversy exists over improved efficacy of S enantiomer (esomeprazole) over
parent racemate (omeprazole). However, a comparison of the clinical outcomes of these products may reveal the
rationale for switching from the racemate to single enantiomer. Since enantiomers of omeprazole are equipotent,
we compared the outcomes of equal doses of each product to see if both actually differ in their efficacy’s or the
reported superiority of S enantiomer is just a dose effect.
Methods: A web search was carried out for randomized controlled trials with head-to-head comparisons of
omeprazole and S-omeprazole. The data were abstracted and after calculating theodd ratios (OR) for the outcomes
reported in each study, the combined overall odd ratios (OR’) were estimated. The random effect inverse variance
method with omeprazole as the reference (OR” = 1) was used.
Results: Out of 1171 studies, 14 were deemed eligible. There was no significant difference in the therapeutic
success between omeprazole and S-omeprazole as a part of triple therapy for the treatment of H. pylori in both
intention-to-treat (OR’, 1.06; CI, 0.83, 1.36; p = 0.63) as well as per-protocol analysis (OR’, 1.07; CI, 0.84, 1.36; p = 0.57).
For the treatment of gastro-oesophageal reflux disease, S-omeprazole was significantly but marginally superior to
the racemate (OR’, 1.18; CI, 1.01, 1.38; p = 0.04). The two products were equipotent in all metrics used to assess
intragastric pH except for the % patients maintaining a 24 h gastric pH above 4 (1.57; CI, 1.04, 2.381; p = 0.03).
Conclusion: The therapeutic benefit of chiral switch of omeprazole is questionable considering the substantially
greater economic burden involved.
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Background
Stereochemical aspects of drug actions and drug disposition
have become a subject of interest since the early 1980s [1].
Most chiral drugs have been used as racemates while the
beneficial effects are often attributed mainly to one of the
enantiomers. Hence, it was intuitively believed that a prod-
uct containing the stereochemically pure enantiomer with
the main pharmacological activity would be superior to its
racemate counterpart. This overwhelming notion has not
been without opposition due to increased toxicity risk in
humans [2] or in experimental animal [3–5]. Nevertheless,
many attempts have been made during the past decades to
switch from racemate to stereochemically pure drug prod-
ucts. This has resulted in the introduction of a few products
in the past decade, e.g., levofloxacin, dexibuprofen and
esomeprazole. At the time of their development, reasonable
rationales for such a switch had been offered without un-
equivocal data on the superiority of the single enantiomers.
For example, omeprazole and S-omeprazole have been the
subject of many randomized controlled trials (RCTs) and
, cohort and case-control studies. However, these studies
and the subsequent systematic reviews [6–12], typically
compared non-comparable doses, i.e., 40 mg S-omeprazole
vs 20 mg racemic omeprazole. In addition, recently, Gellad
et al., who reviewed 4 RCTs that included non-comparative
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doses, concluded mixed evidence for the superiority of the
single S enantiomer over the racemate [13]. Thus, a
comparison of the available data on comparative doses is
needed. From the pharmacological viewpoints, the drug is
not stereoselective since its properties are attributed to both
enantiomers [14]. Its pharmacokinetics, on the other hand,
are stereoselective with the S enantiomer having a higher
bioavailability yielding a greater body exposure than R-
omeprazole. A 40 mg dose of S-omeprazole, therefore,
yields greater than twice the body exposure than a 20 mg
dose of the racemate. Thus, clinical trials that have com-
pared 40 vs 20 mg have not assessed comparative doses.
Only, a 2005 meta-analysis that focused on Helicobacter
pylori (H. pylori) eradication had included a comparison of
equal doses of the racemate and S-omeprazole [15]. The
purpose of this work was to analyse all clinical data on the
efficacy of equal mg doses of S-omeprazole versus that of
racemic omeprazole reported until April 2015. This is with
the realization that a dose of the single S enantiomer will
result in a greater body exposure when compared to an
equal mg dose of the racemate. We stratified the data based
on therapeutic, symptomatic and intragastric pH control
outcomes. We also analyzed available data based on the
type of analysis used; i.e., intention-to-treat and per-




A web search was conducted using a set of keywords
(Appendix 1), in databases including MEDLINE (Medical
Literature Analysis and Retrieval System Online database),
EMBASE (Excerpta Medica database), CINHAL (Cumula-
tive Index to Nursing and Allied Health Literature), IPA
(International Pharmaceutical Abstracts), PASCAL (Dedi-
cated Database for European Science, Technology and
Medicine), Cochrane, EBM (The Evidence-Based Medi-
cine database) and Google Scholar. We looked for studies
reporting comparative RCTs published until April 2015.
The United States Food and Drug Administration (FDA)
and pharmaceutical manufacturer’s websites were also
searched for any relevant literature. Reference lists from
review articles were also checked for any relevant informa-
tion, if available. Two reviewers (W.A. and E.P) independ-
ently reviewed the studies for the inclusion and exclusion
criteria and conflicts were resolved by mutual agreement.
Data analysis
The data from eligible studies was abstracted and ana-
lysed according to published methods [16] and the odds
ratios (ORs) of each study were manually calculated for
each outcome including: (i) therapeutic success; i.e., as part
of triple therapy for eradication of H. pylori or healing of
esophagitis or peptic ulcer; (ii) symptomatic relief of heart
burn, (gastro-oesophageal reflux disease, GERD; (iii) % of
patient with median 24 h intragastric pH above 4. The cal-
culated OR values from all studies were then merged to
create the combined odds ratio (OR’) using the Review
Manager software recommended by Cochrane, and
employing the random effect inverse variance method [17].
For cross-over studies, odd ratios were calculated based on
the matched samples case–control approach [18]. We
chose omeprazole to be the reference (OR’ = 1). For metrics
that OR could not be calculated (i.e., median pH in 24 h,
mean time pH > 4 and % of 24 h with pH > 4) actual mea-
sured values were used to assess the differences.
Selection criteria
Only RCTs carried out in an adult population (>18 years
age) having both S-omeprazole and omeprazole, in head to
head comparisons, at equivalent oral doses, and published
in English were included in our analysis. No outcome re-
striction was considered at this stage. All formulations (cap-
sule, tablet, and suspension, both immediate and delayed
release) with approved doses, regimens, with any salt (mag-
nesium/strontium/sodium), and for any duration of treat-
ment were considered eligible. Both the intention-to-treat
(all data included regardless of whether or not they com-
pleted or received that treatment) and per-protocol
studies were included and analysed separately.
Any study conducted in a paediatric population (age <
18 years), comparing inequivalent doses (40 mg vs.
20 mg), or administering the drug by any route other
than per-oral were excluded from our analysis. Addition-
ally, studies reporting the use of more than two acid
suppressing agents and/or had drug/brand switching
during the trial were also excluded.
Heterogeneity
The variability in outcomes measure (i.e., heterogeneity of
analysis) was determined using Cochrane’s Q and the I2
statistics [19] as reported here (Table 1). The methodo-
logical quality of all eligible studies was assessed using the
previously published Newcastle-Ottawa scale with scores
>5 deemed as acceptable. All eligible studies scored be-
tween 6 and 7 [20].
Strengths and weaknesses
To the best of our knowledge, this systematic review
presents the only exhaustive and up-to-date analysis of
the efficacy of omeprazole (racemate) and esomeprazole
(S enantiomer) at equivalent doses. We have also pro-
vided a comprehensive analysis of all outcomes reported
in the included trials. The fact that most of the eligible
studies were sponsored by the maker of the drugs is the
limitation of our study. Availability and analysis of data
on the prophylactic potential of these drugs would have
been further useful and informative.
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Results
Our search yielded 2467 studies of which, after review of
the title and abstract, 73 were deemed potentially rele-
vant. These studies were retrieved in full text and
reviewed (Fig. 1). Of those, only 14 studies were deemed
eligible after full review [21–34] (Tables 1, 2, 3).
Our final selection included 6 studies [21–26] (Table 1)
reporting the treatment of peptic ulcer secondary to H.
pylori infection with omeprazole or S-omeprazole as
part of a 7-day triple therapy. Four of these studies
[21–24] compared 40 mg daily doses while the other
two [25, 26] used 20 mg daily doses of the two prod-
ucts. Three studies [27–29] (Table 1) were analysed
that included data on the relief from GERD offered
by omeprazole versus S-omeprazole. Five studies were
included which reported [30–34] 24 h median intra-
gastric pH values after administration of omeprazole
and S-omeprazole.
There was no significant difference in the thera-
peutic success between omeprazole and S-omeprazole
as a part of triple therapy for the treatment of H.
pylori in both intention-to-treat (OR’, 1.06; CI, 0.83,
1.36; p = 0.63; n = 6) as well as per-protocol analysis
(OR’, 1.07; CI, 0.84, 1.36; p = 0.57; n = 6). Data for
per-protocol analysis were only available for H. pylori
treatment.
For the treatment of GERD, however, S-omeprazole
was found to be marginally superior to omeprazole
(OR’, 1.18; CI, 1.01, 1.38; p = 0.04; n = 3).
Among the metrics used to compare the effectiveness
of the two products to control intragastric pH (Table 2),
only the percent patients maintaining a 24 h gastric pH
above 4 was significantly greater for S-omeprazole as
compared with racemic omeprazole (OR’: 1.57; CI, 1.04,
2.381; p = 0.03; n = 3). For other pH metrics [35], we
found 5 studies that included outcomes of the median
intragastric pH, duration of intragastric pH > 4, and
percent of patients having intragastric pH > 4 during the
24 h post dose [30–34].
Discussion
Omeprazole is a racemic drug with both enantiomers
entering the parietal cells where, in the presence of acid,
they are converted to an achiral sulphenamide that, in
turn, inhibits the proton pumps therein [36]. The
pharmacological effects of omeprazole are, therefore, not
Table 1 Characteristics of the studies and odds ratio OR (95 % CI) for studies reporting therapeutic and symptomatic relief outcomes
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stereoselective [14]. Its pharmacokinetics, on the
other hand, are stereoselective. Upon its rapid ab-
sorption, the drug undergoes a stereoselective first-
pass metabolism mediated by CYP2C19 in favour of
the R enantiomer. For switching from racemic omep-
razole to its S enantiomer, the following rationale
were offered [37] (i) omeprazole controls intragastric
pH for only 10 h while the S-enantiomer does so for
a longer period; (ii) an increase in dose, does not
add to the beneficial effects of the racemate but it
does so with the S-enantiomer; (iii) there is a less
inter-subject variability in response to S-omeprazole
as compared to the racemate.
Our analysis reveals that, indeed, there is no significant
difference between the two products in the duration of
pH control (Table 2). Indeed, the two products were
equally effective in terms of other pH related outcomes
except for the effectiveness to maintain the value above
4 for which the OR’ was greater for S-omeprazole as
compared with the racemate.
Some investigators have compared the therapeutic
outcomes of the recommended doses of the two drugs;
Fig. 1 Flow diagram of the selection process for randomized controlled trials reporting omeprazole vs esomeprazole (Published until April 2015)
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i.e., 20 mg omeprazole vs 40 mg S-omeprazole. Thus,
since the enantiomers of omeprazole are equipotent, the
comparison has been made between 20 and 40 mg of the
active compound. In addition, since the R enantiomer
undergoes a greater extent of first-pass metabolism, and
the S enantiomer has a nonlinear pharmacokinetics, the
body exposure of 40 mg S-omeprazole is expected to be
even greater than twice that of 20 mg racemic omeprazole.
These studies [6–12], with one exception [15], have re-
ported a greater beneficial effect for 40 mg doses of S-
omeprazole as compared to 20 mg of the racemic drug.
However, our analysed of the available data revealed no
differences between 20 and 40 mg of either omeprazole
or S-omeprazole with respect to both therapeutic and
pH control outcomes (Table 3). This is despite the fact
that a 40 mg dose of S-omeprazole is expected to yield
a substantially greater drug bioavailability than a
20 mg racemate or single enantiomer [37]. This sug-
gests that the examined dosage range may be at the
plateau phase of the dose-effect curve. We were unable
to find data comparing the effect of dose elevation on
GERD.
Our analysis revealed a marginal but significantly greater
effect in the control of GERD for S-omeprazole (OR’, 1.18;
CI, 1.01, 1.38) as compared to omeprazole (reference, OR
1.0) (Table 1). This difference, although statistically sig-
nificant, may be of questionable therapeutic value as
the OR’ is calculated to be very close to unity.
The link between plasma omeprazole concentration and
its beneficial effects is complicated and mainly unknown.
The drug has an apparent plasma t1/2 of appro-
ximately 1 h but a duration of effect of 72 h [38].
Drawing therapeutic inferences based merely on the
pharmacokinetics properties alone and in the absence
of a clear understanding of the kinetics of phar-
macological actions is questionable. It is clear that at
the time of drug development, some advantages were
speculated, however, due to the emergence of more
information over the past decade, a more reliable
analysis of the data has become possible. We can now










Outcome measures as reported in the studies included in our analysis
Odds of 24 h
median intra-gastric
pH > 4 OR
Median intra-gastric
pH within 24 h post
dose (pH)
Mean time pH > 4
within 24 h post
dose (h)
% time duration of
24 h with intra-gastric
pH > 4 (%)
30 O:40 1 31.7 46 1.00 4.5 (4.36- 4.64) 17.8 (17.4-18.5) 62.0 (59.0-65.0)
E: 40 1 31.7 46 2.08 (1.10, 3.96) 4.8 (4.64- 4.92) 19.2 (18.6-19.75) 68.4 (65.4-71.4)
31 O:20 1 58 47 NR 6.4 (6.32- 6.42) NR NR
E: 20 1 59 47 NR 6.4 (6.30- 6.52) NR NR
32 O:20 5 45 42 1.00 3.6 (3.2- 3.9) 10.5 (8.8-12.2) 43.7 (36.7-50.7)
E: 20 5 45 42 1.23 (0.63, 2.38) 4.1 (3.8- 4.5) 12.7 (11.0-14.4) 53.0 (46.0-60.0)
33 O:20 7 21.7 75 NR 5.4 (3.5 - 6.8) 22.6 (20.3–24)] 79.2 (40.0-90.2)
E: 20 7 21.7 75 NR 5.4 (3.5–6.8) 21.1 (17.2–23.8) 81.0 (60.0-90.0)
34 O:20 5 18-6 46 1.00 3.5 (1.6-5.3) 10.4 (3.0–20.2) 44.0 (12.4-83.9)
E:20 5 18-6 46 1.42 (0.56, 3.63) 3.9 (1.9-5.1) 11.3 (3.7–18.0) 48.0 (15.5-75.3)
Overall effect of all
studies combined:
O 1.00 4.39 (3.36, 5.73) 15.24 (12.13, 19.14) 52.01 (39.52, 68.44)








* Statistical significance of difference from referance (p < 0.05), NR- Data not reported
Table 3 The effect of 20 mg and 40 mg doses of omeprazole and S-omeprazole
Drug and Dosage Therapeutic outcome Intra-gastric pH outcome
% of patients cured
(i.e. treatment of
H. pylori) Mean % (SD)
% of patients cured
(i.e. 24 h intra-gastric
pH >4) Mean % (SD)
Median intra-gastric
pH within 24 h post
dose Mean pH (SD)
Mean time pH > 4
within 24 h post
dose Mean h (SD)
% time duration of 24 h
with intra-gastric pH> 4
Mean % (SD)
Omeprazole (O 20) 80.0 (11.3), n = 2 37.5 (9.2), n = 2 4.7 (1.4), n = 4 14.5 (7.0), n = 3 55.6 (20.4), n = 3
Omeprazole (O 40) 79.8 (7.1), n = 4 75.0an = 1 4.5an = 1 17.8an = 1 62.0an = 1
S-Omeprazole (E 20) 83.0 (11.3) n = 2 49.0 (7.1), n = 2 4.9 (1.2), n = 4 15.0 (5.3), n = 3 60.7 (17.8), n = 3
S-Omeprazole (E 40) 84.0 (7.6) n = 4 88.0an = 1 4.8an = 1 19.2an = 1 68.4an = 1
aNo variance since n = 1; NR- Data not reported
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conclude more conclusively that despite the over-
whelming economic success of S-omeprazole, the drug
offers little or no advantage over its parent racemic
product.
Despite the lack of success in therapeutic outcome,
the S enantiomer of omeprazole has been mentioned,
particularly in public and trade media, as an example of
racemic to enantiomer switch success. The market
success of the switch cannot be disputed due to the
ever-growing market share of the acid-controlling agent
(approximately $5 billion in 2013) [39]. This is signifi-
cant as the monthly cost of S-omeprazole is up to over
ten-fold of that of omeprazole.
The advances in stereochemical aspects of drug
action and disposition have enhanced our understand-
ing of the mechanisms behind both the beneficial and
harmful outcomes of drugs. For example, we have
reported that inflammatory disease slows down clear-
ance of racemic verapamil. The extent of this drug-
disease interaction is only 3-fold based on achiral
analysis but 11-fold when the S enantiomer is consid-
ered [40]; pharmacological properties of verapamil are
mainly attributed to its S enantiomer. In addition, the
well-known enantiomeric bioconversion of some drugs
has significantly added to the knowledge of the field
[41, 42] so that many pharmaceutical houses were
prompted to develop new drugs as stereochemically
pure products, or to consider the racemic-enantiomer
switch of available drugs, though there have been very
few successful results [13]. Based on some data gener-
ated using animal models, we have reported that the
stereochemically pure enantiomers of the racemic
nonsteroidal anti-inflammatory drugs do not provide
safer alternatives with regard to the well-known
gastrointestinal side effects of these drugs [3–5]. In
addition, for ofloxacin to levofloxacin and ibuprofen
to dexibuprofen switching, (i.e., another two successful
racemic to enantiomer switches) there are no com-
parative data available to assess the claimed superior-
ity of one over the other. Altogether, it is reasonable
to suggest that, despite the earlier intuitive belief,
stereochemically pure drugs are not necessarily super-
ior to their corresponding racemates [3]. This by no
means implies that the stereochemical aspects of a
drug’s action and dispositions are not of prime import-
ance in clinical pharmacology or toxicology research.
Conclusion
Overall S-omeprazole appeared to be as effective as
omeprazole when used at equivalent doses in treating
ulcers as part of triple therapy, and in controlling 24 h
intragastric pH. For both omeprazole and S-omeprazole
the differences between 20 and 40 mg doses, if any, are
marginal.
Appendix 1: List of search terms and key words used
1. exp omeprazole sulfone/or exp omeprazole/or exp
omeprazole derivative/or omeprazole.mp.
2. omepr$.mp.
3. (Antra or Aspra or Gastroloc or Losectil or Lozeprel
or Mopral or Omepral or Omez or Opal or Ozid or
Rome 20 or Prilosec or Losec or Ulcozol or Segazole
or Zegacid or Zegerid or Losepine).mp. [mp = title,
abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword)
4. (73590-58-6 or 95510-70-6).mp.
5. or/1-4
6. esomeprazole.mp. or exp esomeprazole/ or exp
esomeprazole strontium/
7. esome$.mp.
8. (217087-09-7 or 934714-36-0).mp.
9. (Nexium or Essocam or Esomezol or Racipher or
Opton or Neptor or Nexemezol).mp. [mp = title,
abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer, device trade name, keyword)
10.or/6-9
11.cohort studies.mp. or exp cohort analysis/
12.exp case control study/ or case–control.mp.
13.(randomized controlled trial or random$).mp.
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